GW Seeks To Grow Cannabinoid Products With $179M Offering
GW Pharmaceuticals PLC, a biopharmaceutical company that focuses on the nascent but rapidly developing cannabinoid health product market, said Tuesday that it aims to raise $179 million with a new share...To view the full article, register now.
Already a subscriber? Click here to view full article